Revolution Medicines (NASDAQ:RVMDW – Get Free Report) is expected to release its results after the market closes on Wednesday, November 4th. Analysts expect Revolution Medicines to post earnings of ($2.3451) per share and revenue of $25.58 million for the quarter.
Revolution Medicines Stock Performance
NASDAQ:RVMDW opened at $9.54 on Monday. Revolution Medicines has a 52-week low of $0.34 and a 52-week high of $13.44. The firm’s 50-day moving average is $10.69 and its 200-day moving average is $6.63.
About Revolution Medicines
Revolution Medicines, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company’s research is centered on the RAS signaling pathway, which is frequently altered in tumors and has historically been difficult to target with medicines.
Revolution Medicines is developing a pipeline of RAS(ON) inhibitors designed to block active RAS proteins and related signaling. Its investigational programs include daraxonrasib (RMC-6236), an oral, broad-spectrum RAS(ON) inhibitor, as well as mutation-selective candidates such as RMC-9805 for KRAS G12D and RMC-6291 for KRAS G12C.
Further Reading
- Five stocks we like better than Revolution Medicines
- Strategy Pauses Bitcoin Buys to Focus on Preferred Stock Buybacks
- Uranium Prices Are Near Historic Highs—So Why Hasn’t Cameco Followed?
- Royal Caribbean Buys the Beach as Norwegian Fixes the Ship
- SK hynix Says Memory Demand Beats Supply Through 2030—What It Means for Micron and SanDisk
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
